Systemic Therapeutics Corp.

We are pioneering a new approach to the care of metabolic disorders with first-in-class small molecule SREBP inhibitors

Systemic Therapeutics Uncovers the Protective Mechanism of Caffeine Against Cardiovascular Disease
Hamilton, Ontario--(Newsfile Corp. - February 9, 2022) - Scientists from Systemic Therapeutics Corp. (the "Company" or "SystemicTx") have a new understanding of the protective effects of caffeine on the cardiovascular system. While its stimulant effects have long been characterized, a team of Canadian researchers have discovered how caffeine interacts with key cellular factors to remove cholesterol from the bloodstream.In a landmark study published in Nature Communications, researchers have discovered that caffeine is responsible for triggering a cascade effect that reduces...
2022-02-09 3:43 PM EST
Systemic Therapeutics Announces the Appointment of Its Executive Team
Hamilton, Ontario--(Newsfile Corp. - January 31, 2022) - Systemic Therapeutics Corp. (the "Company" or "SystemicTx") is a pre-clinical stage, biotechnology company specialized in the development of new therapies focusing on the master regulators of lipid metabolism, the sterol regulatory-element binding proteins (SREBP), based on first-in-class SREBP inhibitors. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as dyslipidemia and Non-Alcoholic Steatohepatitis (NASH). SystemicTx is pleased to announce the appointment of...
2022-01-31 3:57 PM EST